TIROFIBAN Drug Patent Profile
When do Tirofiban patents expire, and what generic alternatives are available?
Tirofiban is a drug marketed by Eugia Pharma, Gland, and Nexus. and is included in three NDAs.
The generic ingredient in TIROFIBAN is tirofiban hydrochloride. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the tirofiban hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tirofiban
A generic version of TIROFIBAN was approved as tirofiban hydrochloride by GLAND on April 8th, 2021.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TIROFIBAN?
- What are the global sales for TIROFIBAN?
- What is Average Wholesale Price for TIROFIBAN?
Summary for TIROFIBAN
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| DailyMed Link: | TIROFIBAN at DailyMed |
US Patents and Regulatory Information for TIROFIBAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eugia Pharma | TIROFIBAN HYDROCHLORIDE | tirofiban hydrochloride | SOLUTION;INTRAVENOUS | 216379-001 | May 1, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Nexus | TIROFIBAN HYDROCHLORIDE | tirofiban hydrochloride | SOLUTION;INTRAVENOUS | 213947-001 | Feb 7, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Eugia Pharma | TIROFIBAN HYDROCHLORIDE | tirofiban hydrochloride | SOLUTION;INTRAVENOUS | 216379-002 | May 1, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Gland | TIROFIBAN HYDROCHLORIDE | tirofiban hydrochloride | SOLUTION;INTRAVENOUS | 206888-001 | Apr 8, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Nexus | TIROFIBAN HYDROCHLORIDE | tirofiban hydrochloride | SOLUTION;INTRAVENOUS | 213947-002 | Jul 24, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
